Cargando…
Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial
PURPOSE: Bone marrow-derived, allogeneic, multipotent adult progenitor cells demonstrated safety and efficacy in preclinical models of acute respiratory distress syndrome (ARDS). METHODS: This phase 1/2 trial evaluated the safety and tolerability of intravenous multipotent adult progenitor cells in...
Autores principales: | Bellingan, G., Jacono, F., Bannard-Smith, J., Brealey, D., Meyer, N., Thickett, D., Young, D., Bentley, A., McVerry, B. J., Wunderink, R. G., Doerschug, K. C., Summers, C., Rojas, M., Ting, A., Jenkins, E. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608557/ https://www.ncbi.nlm.nih.gov/pubmed/34811567 http://dx.doi.org/10.1007/s00134-021-06570-4 |
Ejemplares similares
-
The rise and fall of β-agonists in the treatment of ARDS
por: Bassford, Christopher R, et al.
Publicado: (2012) -
PU.1 Is Required for the Developmental Progression of Multipotent Progenitors to Common Lymphoid Progenitors
por: Pang, Swee Heng Milon, et al.
Publicado: (2018) -
Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors
por: Nutt, Stephen L., et al.
Publicado: (2005) -
Evidence for chemokine synergy during neutrophil migration in ARDS
por: Williams, Andrew E, et al.
Publicado: (2017) -
Factor H preserves alternative complement function during ARDS, linked to improved survival
por: Bain, William, et al.
Publicado: (2023)